Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series

Palbociclib is a potent cyclin-dependent kinase (CDK)4/6 inhibitor that disrupts cell cycle progression and has been recently approved in combination with an aromatase inhibitor or fulvestrant as first- and second-line treatment in hormone receptor (HR) , human epidermal growth factor receptor (HER)...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2020-05, Vol.12 (5), p.456-460
Main Authors: Schettini, Francesco, Santo, Irene De, Rea, Carmen G, Viggiani, Martina, Buono, Giuseppe, Angelis, Carmine De, Cardalesi, Cinzia, Lauria, Rossella, Giuliano, Mario, Forestieri, Valeria, Thomas, Guglielmo, Maione, Pierfrancesco, Limite, Gennaro, Accurso, Antonello, Malorni, Luca, Placido, Sabino De, Arpino, Grazia
Format: Article
Language:English
Subjects:
Biopsy
Breast cancer
Case reports
Cell cycle
Cyclin-dependent kinases
Drug dosages
Endocrine therapy
Liver
Medical imaging
Metastasis
Neutropenia
Oncology
Patients
Radiation therapy
Skin
Vertebrae
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Palbociclib is a potent cyclin-dependent kinase (CDK)4/6 inhibitor that disrupts cell cycle progression and has been recently approved in combination with an aromatase inhibitor or fulvestrant as first- and second-line treatment in hormone receptor (HR) , human epidermal growth factor receptor (HER)2 metastatic breast cancer. There is evidence that palbociclib may reverse endocrine therapy resistance and that it may also be added to ongoing endocrine therapy beyond progression to obtain clinical benefit. The aim of the present study was to explore this possibility in 5 patients who received palbociclib + fulvestrant following disease progression while under treatment with fulvestrant alone. The median progression-free survival was not reached during a median follow-up of 25 months, and the most frequent best response was stable disease. Three patients remained under treatment on the last re-evaluation. All patients had highly endocrine-sensitive disease and had previously received fulvestrant for ≥12 months. The hypothesis that a selected subpopulation of patients with HR /HER2 metastatic breast cancer may benefit from the addition of palbociclib to ongoing endocrine therapy beyond disease progression merits further investigation.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2020.2016